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Reply 
In Kaplan et al. (1), Table 2, "Guidelines for Measurement ofBlood 
Pressure," states under cuff size, "The bladder should encircle and 
cover two-thirds of the length of the arm." Therefore, the statement 
that his recommendation s incorrect by Park and Guntheroth is itself 
incorrect. 
The critical feature of an adequate cuff is that the bladder encircle 
the circumference of the arm; the width of the cuff, whether covering 
two thirds or three quarters of the length of the arm, is irrelevant. As 
noted in the 1987 Second Task Force (2) and the more recent 
nomograms composed by Rosner et al. (3), most of the sources for the 
normative l vels were obtained with cuffs that covered two thirds of the 
width and at least three quarters of the circumference. The table 
provided by Park and Guntheroth differs considerably from those of 
both "official" sets of data because they appear to have been taken 
from only two of the nine sources used by the other two "official" 
recommendations. 
Therefore, the recommendations provided in Table 2 of the 26th 
Bethesda Conference (1) are correct and should be followed. 
NORMAN M. KAPLAN, MD, FACC 
Chief, Hypertension Division 
University of Texas Southwestern Medical Center 
5323 Harry Hines Boulevard 
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Fluosol in Myocardial Reperfusion Injury 
Recently, Kolodgie et al. (1) further examined the mechanism for the 
beneficial effects of Fluosol on myocardial reperfusion i jury. Fluosol 
is a complex mixture of oxygen-carrying perfluorocarbons emulsified 
by a surfactant, poloxamer 188. Both Fluosol and poloxamer 188 have 
previously been shown (2-6) to significantly enhance myocardial 
salvage in both canine and rabbit models of regional ischemia. This 
benefit has been observed in the absence of hyperoxic reperfusion 
(3,4,6). Both Fluosol and its emulsifier have also been shown (2-4,7) 
to significantly inhibit neutrophil infiltration i to the reperfused tissue 
and to markedly attenuate various indexes of neutrophil activation ex 
vivo. In their study, Kolodgie t al. (1) reported that both Fluosol and 
poloxamer 188 alone reduced reperfusion i jury significantly and that 
oxygen was required for both compounds to exert their beneficial 
effects. The authors hypothesized that the amelioration i  reperfusion 
injury was related to enhanced regional blood flow in the setting of 
hyperoxic reperfusion tothe postischemic myocardium and that it was 
not related to effects on neutrophils. 
Numerous tudies upport the hypothesis that neutrophils play an 
important role in the pathogenesis of myocardial reperfusion i jury. 
We have previously shown (2,3,7,8) that the mechanism of action of 
Fluosol appears to be primarily mediated through poloxamer 188 
suppressing neutrophil activation in the reperfused tissue. This sup- 
pression results through the phagocytic uptake by the neutrophils of 
the Fluosol particles emulsified into a micellar structure by the 
poloxamer 188. This action occurs throughout the circulation, resulting 
in a subsequent refractoriness of the neutrophils to further activation 
in the damaged tissue. In contrast, he results by Kolodgie t al. (1) do 
not suggest a role for neutrophils in the mechanism of action by 
Fluosol. Their ex vivo neutrophil experiments were performed in the 
presence of cytochalasin B. This drug is used in superoxide anion 
assays to enhance receptor-mediated activation of these cells (9). In 
contrast, cytochalasin B prevents uperoxide anion generation in 
response to a particulate stimulus by inhibiting the phagocytic process 
(9). Furthermore, we (7) have used cytochalasin B as a way of 
demonstrating that the mechanism of activation of neutrophils by 
Fluosol resulting in the subsequent refractoriness is through phagocy- 
tosis. Therefore, the failure of Kolodgie et al. to show an effect of 
Fluosol and the poloxamer on neutrophil function was secondary to 
preincubation f the cells with cytochalasin B.
The authors also suggest (1) that the failure to demonstrate a 
significant difference in the levels of myeloperoxidase in the reperfused 
tissue between treated or untreated rabbits further supports their claim 
that Fluosol's major effects on reperfusion injury is unrelated to 
neutrophil effects. One possible xplanation is that the dose of Fluosol 
utilized in their present study was not optimal. This is supported by 
previous tudies from this group (5) that demonstrate that Fluosol in 
a dose of 30 ml/kg induced almost a 100% greater increase in 
myocardial salvage compared with the dose utilized in the present 
study (1) (20 ml/kg, which proved to be the minimally effective dose 
previously). Studies reported from our laboratory (6) utilizing a similar 
model have demonstrated that Fluosol in a dose of 30 ml/kg signifi- 
cantly reduced myocardial reperfusion i jury in the absence of oxygen. 
Therefore, the failure of Kolodgie t al. to use a larger dose of Fluosol 
may explain the failure to detect an effect in neutrophil infiltration in 
the reperfused myocardinm as measured with myeloperoxidase con- 
tent. 
Finally, the results of Kolodgie et al. suggest that the actions of 
Fluosol resulting from poloxamer 188 to increase hyperoxic reperfu- 
sion may be limited by a type II error. The area of necrosis/area at risk 
reported oes not appear to be different for poloxamer 188 in the 
presence or absence of oxygen, 39.7 _+ 3.2% versus 42.9 _+ 4.7%, 
respectively, although only the former was found to be significantly 
different from the untreated value of 54.7 _+ 2.7%. 
Our previous investigations clearly suggest hat the surfactant 
component of Fluosol is responsible for the beneficial effects of 
Fluosol, as also reported by Kolodgie et al. (1). However, our results 
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suggest hat an important mechanism for the actions of Fluosol is 
through alteration of various neutrophil functions. Although we can- 
not completely eliminate a role for hyperoxic reperfusion or other 
actions in the beneficial effects of Fluosol (8), the current study does 
not support the finding that hyperoxic reperfusion is the primary 
mechanism or that the effects of Fluosol are not mediated through 
neutrophils. 
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Reply 
Murray et al. raise several questions concerning the methodologies 
used in our assessment of polymorphonuclear leukocyte (PMN) func- 
tion (1). As Murray et al, point out, previous in vitro evidence supports 
the premise that the detergent component of Fluosol-DA, poloxamer 
188, dfrectly activates PMNs through phagocytosis (2). In light of these 
findings, these investigators propose that either Fluosol-DA or polox- 
amer 188 activate PMNs while in circulation. Activated PMNs would 
thus be refractory to subsequent stimulation and lose their ability to 
promote infarct extension upon reperfusion (2). Murray et al. take 
issue with our study because we exposed PMNs to cytochalasin B (an 
agent that blocks phagocytosis) before assessment of their function. 
Cytochalasin B is commonly used in PMN superoxide assays because it 
enhances both the rate and amount of superoxide anion ('O2-) 
production. This effect most likely occurs by inhibiting phagocytic 
vacuole formation, which prevents the access of cell surface-generated 
superoxide anion to cytoplasmic superoxide dismutase. Therefore, 
more superoxide anion is exposed to the detector chromogen ferricy- 
tochrome C (3). 
In our study, PMNs were pretreated with cytochalasin B for 
superoxide anion and lysozyme release assays. The PMNs were 
isolated at 3 h of reperfusion only after exposing the ischemic 
reperfused animal to Flnosol-DA or poloxamer 188 in vivo. For 
chemotaxis assays, PMNs were not pretreated with cytochalasin B
because it prevents the polymerization of actin and therefore would 
impair chemotactic responses (4). If the hypothesis proposed by 
Murray et al. is correct, one would expect that PMNs isolated after 
treating rabbits with Fluosol-DA and poloxamer in vivo would exhibit 
"burnout" and resistance to stimulation. This was clearly not the case; 
PMNs from Fluosol-DA- and poloxamer 188-treated rabbits re- 
sponded equally as well or better than control or sham operated 
(noninfarcted) animals (unpublished observations) to receptor- 
mediated activation. Furthermore, the myocardial myeloperoxidase 
content between groups was similar, suggesting that the degree of 
PMN infiltration in the ischemic region was not influenced by treat- 
ment. 
We disagree with the comment by Murray et al. that the dose of 
Fluosol-DA used in the study (20 mg/ml) was not high enough to 
demonstrate changes in PMN function. The efficacy of this concentra- 
tion of Fluosol-DA to reduce infarct size was demonstrated both in the 
present study in question and in a previous tudy in our laboratory (5). 
With regard to the poloxamer infarct size data, a recent study by 
Schaer et al. (6) utilizing the canine infarct model failed to demon- 
strate infarct size reduction with poloxamer 188 in normoxic reper- 
fused hearts when it was administered as an intravenous bolus followed 
by a 4-h infusion, which is consistent with the finding in the present 
study (1). However, infarct size reduction was significantly reduced 
after a prolonged 48-h infusion of poloxamer 188 (6). Although in vitro 
treatment of PMNs with poloxamer 188 enhanced superoxide anion 
production and suppressed chemotaxis (6), this agent also has hemo- 
rheologic properties eparate from neutrophil effects that may affect 
infarct size after reperfusion. 
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